Elliott J Mufson1, Sylvia E Perez1, Muhammad Nadeem1, Laura Mahady1, Nicholas M Kanaan2, Eric E Abrahamson3,4, Milos D Ikonomovic3,4, Fiona Crawford5, Victor Alvarez6, Thor Stein6, Ann C McKee6. 1. a Department of Neurobiology , Barrow Neurological Institute , Phoenix , AZ , USA. 2. b Department of Translational Science and Molecular Medicine, College of Human Medicine , Michigan State University , Grand Rapids , MI , USA. 3. c Departments of Neurology and Psychiatry , University of Pittsburgh , Pittsburgh , PA , USA. 4. d Geriatric Research Education and Clinical Center , VA Pittsburgh Healthcare System , Pittsburgh , PA , USA. 5. e Roskamp Institute , Sarasota , FL , USA. 6. f VA Boston HealthCare System, Alzheimer Disease Center and CTE Program and Departments of Neurology and Pathology , Boston University School of Medicine , Boston , MA , USA.
Abstract
OBJECTIVE: To test the hypothesis that the nucleus basalis of Meynert (nbM), a cholinergic basal forebrain (CBF) cortical projection system, develops neurofibrillary tangles (NFTs) during the progressive pathological stages of chronic traumatic encephalopathy (CTE) in the brain of athletes. METHOD: To characterize NFT pathology, tau-antibodies marking early, intermediate and late stages of NFT development in CBF tissue obtained at autopsy from eighteen former athletes and veterans with a history of repetitive mild traumatic brain injury (TBI) were used. RESULTS: Analysis revealed that cholinergic nbM neurons develop intracellular tau-immunoreactive changes progressively across the pathological stages of CTE. In particular, there was an increase in pre-tangle (phosphorylated pS422) and oligomeric (TOC1 and TNT1) forms of tau in stage IV compared to stage II CTE cases. The nbM neurons also displayed pathologic TDP-43 inclusions and diffuse extracellular and vascular amyloid-β (Aβ) deposits in CTE. A higher percentage of pS422/p75NTR, pS422 and TNT1 labelled neurons were significantly correlated with age at symptom onset, interval between symptom onset and death and age at death. CONCLUSION: The development of NFTs within the cholinergic nbM neurons could contribute to an axonal disconnection in CTE. Further studies are needed to determine the mechanism driving NFT formation in the nbM neurons and its relation to chronic cognitive dysfunction in CTE.
OBJECTIVE: To test the hypothesis that the nucleus basalis of Meynert (nbM), a cholinergic basal forebrain (CBF) cortical projection system, develops neurofibrillary tangles (NFTs) during the progressive pathological stages of chronic traumatic encephalopathy (CTE) in the brain of athletes. METHOD: To characterize NFT pathology, tau-antibodies marking early, intermediate and late stages of NFT development in CBF tissue obtained at autopsy from eighteen former athletes and veterans with a history of repetitive mild traumatic brain injury (TBI) were used. RESULTS: Analysis revealed that cholinergic nbM neurons develop intracellular tau-immunoreactive changes progressively across the pathological stages of CTE. In particular, there was an increase in pre-tangle (phosphorylated pS422) and oligomeric (TOC1 and TNT1) forms of tau in stage IV compared to stage II CTE cases. The nbM neurons also displayed pathologic TDP-43 inclusions and diffuse extracellular and vascular amyloid-β (Aβ) deposits in CTE. A higher percentage of pS422/p75NTR, pS422 and TNT1 labelled neurons were significantly correlated with ageat symptom onset, interval between symptom onset and death and ageatdeath. CONCLUSION: The development of NFTs within the cholinergic nbM neurons could contribute to an axonal disconnection in CTE. Further studies are needed to determine the mechanism driving NFT formation in the nbM neurons and its relation to chronic cognitive dysfunction in CTE.
Authors: Lee E Goldstein; Andrew M Fisher; Chad A Tagge; Xiao-Lei Zhang; Libor Velisek; John A Sullivan; Chirag Upreti; Jonathan M Kracht; Maria Ericsson; Mark W Wojnarowicz; Cezar J Goletiani; Giorgi M Maglakelidze; Noel Casey; Juliet A Moncaster; Olga Minaeva; Robert D Moir; Christopher J Nowinski; Robert A Stern; Robert C Cantu; James Geiling; Jan K Blusztajn; Benjamin L Wolozin; Tsuneya Ikezu; Thor D Stein; Andrew E Budson; Neil W Kowall; David Chargin; Andre Sharon; Sudad Saman; Garth F Hall; William C Moss; Robin O Cleveland; Rudolph E Tanzi; Patric K Stanton; Ann C McKee Journal: Sci Transl Med Date: 2012-05-16 Impact factor: 17.956
Authors: David X Cifu; Brent C Taylor; William F Carne; Douglas Bidelspach; Nina A Sayer; Joel Scholten; Emily Hagel Campbell Journal: J Rehabil Res Dev Date: 2013
Authors: Nicholas M Kanaan; Gerardo A Morfini; Nichole E LaPointe; Gustavo F Pigino; Kristina R Patterson; Yuyu Song; Athena Andreadis; Yifan Fu; Scott T Brady; Lester I Binder Journal: J Neurosci Date: 2011-07-06 Impact factor: 6.167
Authors: Kristina R Patterson; Christine Remmers; Yifan Fu; Sarah Brooker; Nicholas M Kanaan; Laurel Vana; Sarah Ward; Juan F Reyes; Keith Philibert; Marc J Glucksman; Lester I Binder Journal: J Biol Chem Date: 2011-05-06 Impact factor: 5.157
Authors: Steven T DeKosky; Milos D Ikonomovic; Scot D Styren; Laurel Beckett; Stephen Wisniewski; David A Bennett; Elizabeth J Cochran; Jeffrey H Kordower; Elliott J Mufson Journal: Ann Neurol Date: 2002-02 Impact factor: 10.422
Authors: Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson Journal: Acta Neuropathol Date: 2019-02-07 Impact factor: 17.088
Authors: Elliott J Mufson; Bin He; Stephen D Ginsberg; Benjamin A Carper; Gayle S Bieler; Fiona Crawford; Victor E Alvarez; Bertrand R Huber; Thor D Stein; Ann C McKee; Sylvia E Perez Journal: J Neurotrauma Date: 2018-04-05 Impact factor: 5.269
Authors: Andrew Kneynsberg; Benjamin Combs; Kyle Christensen; Gerardo Morfini; Nicholas M Kanaan Journal: Front Neurosci Date: 2017-10-17 Impact factor: 4.677